Home Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO
 

Keywords :   


Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO

2014-05-31 19:24:01| Logistics - Topix.net

Clovis Oncology today announced results from an ongoing Phase 1/2a monotherapy study evaluating lucitanib, the Company's novel, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 , vascular endothelial growth factor receptors 1 through 3 and platelet-derived growth factor receptors alpha and beta .

Tags: results study reports phase

Category:Transportation and Logistics

Latest from this category

All news

25.11Eastern North Pacific Tropical Weather Outlook
25.11Atlantic Tropical Weather Outlook
25.11Atlantic Tropical Weather Outlook
25.11Eastern North Pacific Tropical Weather Outlook
25.11Eastern North Pacific Tropical Weather Outlook
25.11Atlantic Tropical Weather Outlook
24.11Atlantic Tropical Weather Outlook
24.11Eastern North Pacific Tropical Weather Outlook
Transportation and Logistics »
25.111/18CTS-V
25.11
25.111
25.11ARS 10+ EHERO 3
25.11 16MGL HG
25.11
25.11GREENMAX 4470 22600Ace4
25.11
More »